P1089: Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitisECCO'25Year: 2025
Authors: Sturm, A.(1)*;Sebastian , S.(2);Faye, A.S.(3);Armuzzi, A.(4);Buisson, A.(5);Halfvarson, J.(6);Zeissig, S.(7,8);Kochar, B.(9);Maier, S.(10);Redondo, I.(10);Moses, R.E.(10);Keohane, A.(11);Watanabe, K.(12);
(1)DRK Kliniken Berlin Westend, Department of Gastroenterology, Berlin, Germany;(2)Hull University Teaching Hospitals, IBD Unit, Hull, United Kingdom;(3)NYU Langone Health, Inflammatory Bowel Disease Center, New York, United States;(4)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;(5)Université Clermont Auvergne, Inserm- 3iHP- CHU Clermont-Ferrand- Service d’Hépato-Gastroentérologie, Clermont-Ferrand, France;(6)Örebro University, Department of Gastroenterology, Örebro, Sweden;(7)University Medicine Greifswald, Department of Internal Medicine A, Greifswald, Germany;(8)Technische Universität TU Dresden, Medical Faculty, Dresden, Germany;(9)Massachusetts General Hospital, Gastroenterology Unit, Boston, United States;(10)Eli Lilly and Company, Lilly Immunology, Indianapolis, United States;(11)HaaPACS GmbH, Statistics Europe, Schriesheim, Germany;(12)The University of Toyama, Department of Internal Medicine for Inflammatory Bowel Disease, Toyama, Japan;
1) D'Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis [published correction appears in N Engl J Med. 2023 Aug 24;389(8):772. doi: 10.1056/NEJMx230004]. N Engl J Med. 2023;388(26):2444-2455. doi:10.1056/NEJMoa2207940
2) Ananthakrishnan AN, Nguyen GC, Bernstein CN. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. Gastroenterology. 2021;160(1):445-451. doi:10.1053/j.gastro.2020.08.060
3) Sturm A, Maaser C, Mendall M, et al. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. J Crohns Colitis. 2017;11(3):263-273. doi:10.1093/ecco-jcc/jjw188
P1090: Increased advanced therapy prescribing correlates with decreased colectomy rates in ulcerative colitis: a twenty-year population-based cohort study in Lothian, ScotlandECCO'25Year: 2025
Authors: Elford, A.(1)*;Constantine-Cooke, N.(2);Jenkinson, P.(1);Gros, B.(1);Plevris, N.(1);Lyons, M.(1);Ong, S.(1);Greenlees, N.(1);O'Hare, C.(1);Din, S.(1);Noble, C.(1);Jones, G.(1);Arnott, I.(1);Lees, C.(1);
(1)Western General Hospital- NHS Lothian, Edinburgh IBD Unit, Edinburgh, United Kingdom;(2)Institute of Genetics and Cancer- University of Edinburgh- Western General Hospital- Edinburgh- Scotland- UK, MRC Human Genetics Unit, Edinburgh, United Kingdom;
P1091: Trends in length of stay and steroid use in patients admitted with Acute Severe Ulcerative Colitis: Impact of intensified or accelerated infliximab dosingECCO'25Year: 2025
Authors: Bartlett , R.(1);Mohamedrashed , M.(1);Yogakanthi , S.(1);Chew , M.(1);Nedumannil , L.(1);Pearce , R.(1);Lucas , S.(1);Chauhan , A.(1);Lewis , D.(1);Kashkooli , S.(1);Garg , M.(1)*;
(1)Northern Health, Gastroenterology, Melbourne, Australia;
P1092: Real-life durability and utilization of biologics in pediatric inflammatory bowel disease: results from Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP) IBD registry.ECCO'25Year: 2025
Authors: Lega, S.(1)*;Manuela, G.(1);D'Arcangelo , G.(2);Di Pasquale, V.(3);Scarallo, L.(4);Ancona, S.(5);Fedele, F.(6);Zuin, G.(7);Graziano, F.(8);Norsa, L.(9);Gatti, S.(10);Illiceto, M.T.(11);Felici, E.(12);Corpino, M.(13);Pavanello, P.(14);Cozzali, R.(15);Alvisi, P.(16);Belluca, S.(17);Banzato, C.(18);Penagini, F.(19);Marseglia, A.(20);Faraci, S.(21);Luini, C.(22);Strisciuglio, C.(23);Moretti, C.(24);Martinelli, M.(6);Arrigo, S.(5);Lionetti, P.(4);Romano, C.(3);Aloi, M.(2);Bramuzzo, M.(1);
(1)Institute for Maternal and Child Health- IRCCS Burlo Garofolo, Pediatrics, Trieste, Italy;(2)Pediatric Gastroenterology Unit- Sapienza University – Umberto I, Pediatrics, Rome, Italy;(3)Pediatric Gastroenterology and Cystic Fibrosis Unit- Department of Human Pathology in Adulthood and Childhood "G. Barresi"- University Hospital "G. Martino", Pediatrics, Messina, Italy;(4)Gastroenterology and Nutrition Unit- Meyer Children Hospital IRCCS, Pediatrics, Florence, Italy;(5)Pediatric Gastroenterology and Endoscopy Unit – IRCCS Istituto Giannina Gaslini, Pediatrics, Genova, Italy;(6)Department of Translational Medical Science- Section of Pediatrics- University of Naples "Federico II, Pediatrics, Naples, Italy;(7)Pediatrics Department- Fondazione IRCCS San Gerardo dei Tintori, Pediatrics, Monza, Italy;(8)Pediatric Unit- Villa Sofia- Cervello Hospital- Palermo- Italy, Pediatrics, Palermo, Italy;(9)Paediatric Hepatology Gastroenterology and Transplantation- ASST Papa Giovanni XXIII, Pediatrics, Bergamo, Italy;(10)Università Politecnica delle Marche, Pediatrics, Ancona, Italy;(11)Paediatric Gastroenterology and Endoscopy- Department of Pediatrics – Ospedale Civile “Spirito Santo”, Pediatrics, Pescara, Italy;(12)Pediatric and Pediatric Emergency Unit- Children Hospital- AO SS Antonio e Biagio e C. Arrigo, Pediatrics, Alessandria, Italy;(13)Pediatric and Rare Disease Clinic- Microcitemico Hospital, Pediatrics, Cagliari, Italy;(14)Gastroenterology Unit- Departement pf Pediatrics Regional Hospital, Pediatrics, Treviso, Italy;(15)Pediatric Division- Università degli Studi di Perugia, Pediatrics, Perugia, Italy;(16)Gastroenterology Unit- Maggiore Hospital, Pediatrics, Bologna, Italy;(17)Gastroenterologia Pediatrica- Ospedale Infantile Regina Margherita- Dipartimento di Scienze della Sanità Pubblica e Pediatriche- Università degli Studi di Torino, Pediatrics, Turin, Italy;(18)Pediatric Division- University Hospital of Verona, Pediatrics, Verona, Italy;(19)Vittore Buzzi Children's Hospital- University of Milan, Pediatrics, Milan, Italy;(20)Fondazione IRCCS Casa Sollievo della Sofferenza- Divisione di Pediatria, Pediatrics, San Giovanni Rotondo, Italy;(21)Digestive Diseases Unit- Bambino Gesù Children's Hospital, Pediatrics, Rome, Italy;(22)Hospital “F. Del Ponte”, Pediatrics, Varese, Italy;(23)Depart. Woman- Child and General and specialistic Surgery. University of Campania Vanvitelli, Pediatrics, Naples, Italy;(24)Division of pediatrics- ASST GOM Niguarda, Pediatrics, Milan, Italy; SIGENP IBD Study Group
P1093: Personalized Tasty&Healthy whole-food diet for maintaining remission in children and adults with Crohn’s disease: results from the MyTasty open-label trialECCO'25Year: 2025
Authors: Plotkin, L.(1,2)*;Aharoni Frutkoff, Y.(1);Shavit, Z.(1);Focht, G.(1);Buchuk, R.(1);Lev-Zion, R.(1);Ledder, O.(1);Assa, A.(1);Sigall Boneh, R.(3);Weiss, B.(4);Slae , M.(5);Dotan, I.(6);Kierkuś, J.(7);Broide, E.(8);Griffiths, A.(9);Naftali, T.(10);Aloi, M.(11);Yerushalmy-Feler, A.(12);Schwerd, T.(13);Reifen, R.(2);Turner, D.(1);
(1)Shaare Zedek Medical Center, The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(2)The Hebrew University of Jerusalem, Institute of Biochemistry- Food Science and Nutrition Robert H. Smith Faculty of Agriculture- Food and Environment, Rehovot, Israel;(3)The E. Wolfson Medical Center- Pediatric Gastroenterology and Nutrition Unit, Pediatric Gastroenterology and Nutrition Unit, Holon, Israel;(4)Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel;(5)Hadassah Ein Kerem, The Pediatric Gastroenterology Center, Jerusalem, Israel;(6)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(7)Children’s Memorial Health Institute, Pediatric Gastroenterology Unit, Warsaw, Poland;(8)Assaf Harofeh Medical Center, Pediatric Gastroenterology Unit, Zerifin, Israel;(9)Hospital for Sick Children, Pediatric Gastroenterology, Toronto, Canada;(10)Meir Hospital, Gastroenterology, Kfar Saba, Israel;(11)Sapienza University of Rome, Dept. of Pediatric Gastroenterology, Rome, Italy;(12)Tel Aviv Sourasky Medical Center, Pediatric Gastroenterology, Tel Aviv, Israel;(13)LMU München, Dr von Hauner Children`s Hospital, Munich, Germany; T&H
P1094: Serum Chitinase 3-like-1 (CHI3L1) is correlated to fecal calprotectin levels in IBD patients during pregnancyECCO'25Year: 2025
Authors: Schweistein, H.(1)*;Rave, A.(2);Glusman Bendersky, A.(1);Ollech, J.E.(1);Ariella , B.G.S.(3);
(1)Rabin Medical center- affiliated with Tel Aviv University, Gastroenterology Division, Petah Tikva, Israel;(2)Clalit health services- affiliated with Tel aviv University, Department of Family Medicine, Sharon Shomron, Israel;(3)Shaare-Zedek Medical Center- affiliated with Hebrew University, IBD center- Digestive Diseases Institute, Jerusalem, Israel;
P1095: Switching from Ustekinumab to Risankizumab Improves Outcomes in Crohn’s Disease: A Single-Centre Real-World Data AnalysisECCO'25Year: 2025
Authors: Qazi, U.(1)*;Padley, J.(1);Colwill, M.(1,2);Mehta, S.(1);Donovan, F.(1);Francisco Alves, A.M.(1);Pollok, R.(1,2);Poullis, A.(1,2);Patel, K.(1);Honap, S.(1,3);
(1)St George's University Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom;(2)City St George's- University of London, Institute of Infection and Immunity, London, United Kingdom;(3)King's College London, School of Immunology and Microbial Sciences, London, United Kingdom;
1. Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D’Haens G, Ferrante M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. N Engl J Med. 2024 Jul 18;391(3):213–23
P1096: The predictive value of intestinal ultrasound for treatment response in Inflammatory Bowel Disease: a systematic review and pooled data analysisECCO'25Year: 2025
Authors: Vos, H.(1)*;Teichert, C.(2);de Voogd, F.(2);Pruijt, M.(2);D'Haens, G.(2);Benninga, M.(1);Koot, B.(1);Gecse, K.(2);
(1)Emma Children’s Hospital- Amsterdam UMC, Department of Pediatric Gastroenterology and Nutrition, Amsterdam, The Netherlands;(2)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P1097: Phase 1/2 study to assess safety, tolerability, and efficacy of XmAb942 (anti-TL1A) in healthy participants and participants with ulcerative colitisECCO'25Year: 2025
Authors: Hung, K.(1)*;Aggarwal, S.(1);Gargosky, S.(2);Peterson, C.(3);Ramanujan, S.(4);Banfield , C.(5);Manukyan , Z.(6);Hassan-Zahraee, M.(1);Kanodia, J.(7);Woo, J.(7);Szymkowski, D.(8);Visonneau, S.(9);Burington, B.(10);Trout, C.(11);Leone, D.(11);Dahiyat, B.(12);Gujrathi, S.(5);Desjarlais, J.(13);
(1)Xencor- Inc., Clinical Development, Pasadena, United States;(2)Xencor- Inc.- through its subsidiary Gale- Inc., Clinical Operations, Pasadena, United States;(3)Xencor- Inc.- through its subsidiary Gale- Inc., Regulatory Affairs, Pasadena, United States;(4)Xencor- Inc.- through its subsidiary Gale- Inc., Translational Biology, Pasadena, United States;(5)Xencor- Inc.- through its subsidiary Gale- Inc., Clinical Development, Pasadena, United States;(6)Xencor- Inc., Biostatistics, Pasadena, United States;(7)Xencor- Inc., Translational Biology, Pasadena, United States;(8)Xencor- Inc., Preclinical Operations, Pasadena, United States;(9)Xencor- Inc., Clinical Operations, Pasadena, United States;(10)Xencor- Inc., Biometrics, Pasadena, United States;(11)Xencor- Inc., Corporate Strategy, Pasadena, United States;(12)Xencor- Inc., Chief Executive Officer, Pasadena, United States;(13)Xencor- Inc., Chief Scientific Officer, Pasadena, United States;
Clinical trials identification: NCT06619990
P1098: The Clinical Spectrum of Acute Severe Ulcerative Colitis in the Biologic EraECCO'25Year: 2025
Authors: SinghD.M., A.(1)*;Luthra, M.(1);Bhardwaj, A.(1);Mahajan, R.(1);Sharma, R.(1);Singh, D.(1);Jain, D.(1);Goyal, O.(1);Mehta, V.(1);Kaur, K.(2);Gupta, Y.(1);Midha, V.(3);Sood, A.(1);
(1)Dayanand Medical College and Hospital, Gastroenterology, Ludhiana, India;(2)Dayanand Medical College and Hospital, Pharmacology, Ludhiana, India;(3)Dayanand Medical College and Hospital, Medicine, Ludhiana, India;
P1099: Simple magnetic resonance imaging markers are non-inferior measures of treatment response compared to complex disease activity scores in patients with active Crohn’s diseaseECCO'25Year: 2025
Authors: Nejatbakhsh, E.(1)*;Rafaelsen, S.R.(2,3);Brodersen, J.B.(1,2);Knudsen, T.(1,2);Kjeldsen, J.(4,5,6);Juel, M.A.(1);Jensen, M.D.(1,2);
(1)Esbjerg and Grindsted Hospital – University Hospital of Southern Denmark, Department of Internal Medicine- Section of Gastroenterology, Esbjerg, Denmark;(2)University of Southern Denmark, Department of Regional Health Research, Odense, Denmark;(3)Lillebaelt Hospital – University Hospital of Southern Denmark, Department of Radiology, Vejle, Denmark;(4)Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark;(5)Odense University Hospital, OPEN Odense Patient data Explorative Network, Odense, Denmark;(6)University of Southern Denmark, Research Unit of Medical Gastroenterology- Department of Clinical Research, Odense, Denmark;
P1100: Effectiveness of Risankizumab in Crohn’s Disease, our real-world experience: Clinical, Biochemical and Ultrasonographic responses. A single centre, observational, retrospective study.ECCO'25Year: 2025
Authors: Moralejo Lozano, Ó.(1)*;Jarrín Pesantes, V.C.(1);Abanades Tercero, M.(1);Ruano Pérez, L.(1);Salmoral Luque, R.(1);Muñoz Rosas, C.(1);Gómez Rodriguez, R.Á.(1);
(1)Hospital Universitario de Toledo, Gastroenterology and Hepatology Department, Toledo, Spain;
- D'Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015-2030. doi:10.1016/S0140-6736(22)00467-6.
- Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031-2046. doi:10.1016/S0140-6736(22)00466-4.
- Ilvemark JFKF, Hansen T, Goodsall TM, et al. Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement. J Crohns Colitis. 2022;16(4):554-580. doi:10.1093/ecco-jcc/jjab173.
- Barreiro-de Acosta M, Nieto García L, Poncela M, et al. OP043 Real-world short-term effectiveness of Risankizumab in refractory Crohn’s disease: RISANCROHN study from the ENEIDA registry. UEG Week 2024 Oral Presentations. United European Gastroenterol J. 2024;12(Suppl 8): 2050-6406. doi.org/10.1002/ueg2.12614.
P1101: Real-world effectiveness and safety of Risankizumab in Crohn’s DiseaseECCO'25Year: 2025
Authors: McShane, C.(1)*;Olivera Sendra, P.A.(1);Kim, J.(1);Milgrom, R.(1);Stempak, J.(1);Nguyen, G.(1);Weizman, A.V.(1);Croitoru, K.(1);Gallinger, Z.(1);Huang, V.(1);Steinhart, H.(1);Targownik, L.(1);Lee, S.H.(1);Silverberg, M.(1);
(1)Mount Sinai Hospital, The Zane Cohen Centre for Digestive Diseases, Toronto, Canada;
P1102: Albumin predicts post-operative complications in Acute Severe Ulcerative ColitisECCO'25Year: 2025
Authors: Hodges, P.(1)*;Phillips, J.(2);King, H.(3);Creamer, J.(4);Kitchin, A.(4);Carter, O.(5);Tyrrell-Price, J.(2);
(1)Somerset NHS Foundation Trust, Gastroenterology, Yeovil, United Kingdom;(2)University Hospitals Bristol and Weston NHS Foundation Trust, Gastroenterology, Bristol, United Kingdom;(3)Gloucestershire Hospitals NHS Foundation Trust, Gastroenterology, Gloucester, United Kingdom;(4)Somerset NHS Foundation Trust, Gastroenterology, Taunton, United Kingdom;(5)Royal United Hospitals Bath NHS Foundation Trust, Gastroenterology, Bath, United Kingdom; Severn and Peninsula Research in Gastroenterology Trainee Network (SPRinG)
1. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97(3):404-9.
P1103: Thromboembolic and cardiovascular risk profiles in ulcerative colitis patients initiating advanced therapies: a single-center studyECCO'25Year: 2025
Authors: Calvez, V.(1)*;Cuccia, G.(2);Del Gaudio, A.(2);Capobianco, I.(2);Parisio, L.(2);Gasbarrini, A.(2);Scaldaferri, F.(2);Carbone, L.(3);Pugliese, D.(2);
(1)Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli Dipartimento di scienze mediche e chirurgiche, Rome, Italy;(2)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Catholic University of Rome, Department of Translational Medicine and Surgery, Rome, Italy;(3)Ospedale Isola Tiberina Gemelli Isola- Rome Medicina d'Urgenza e Medicina Interna- Rome- Italy, Medicina d'Urgenza e Medicina Interna, Rome, Italy;
References
[1] Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel J-F. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies. Journal of Crohn’s and Colitis 2014;8:469–79. https://doi.org/10.1016/j.crohns.2013.09.021.
[2] Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022;386:316–26. https://doi.org/10.1056/NEJMoa2109927.
[3] EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders | European Medicines Agency n.d. https://www.ema.europa.eu/en/news/ema-confirms-measures-minimise-risk-serious-side-effects- janus-kinase-inhibitors-chronic-inflammatory-disorders (accessed April 25, 2024).
[4] Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC, Sperling LS, Virani SS, et al. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology 2019;73:3153–67. https://doi.org/10.1016/j.jacc.2018.11.005.
P1104: Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinibECCO'25Year: 2025
Authors: SinghD.M., A.(1)*;Bhardwaj, A.(1);Jain, D.(1);Sharma, R.(1);Singh, D.(1);Mahajan, R.(1);Kaur, K.(2);Singh, A.(3);Narang, V.(3);Kaur, H.(3);Singh, M.(4);Gupta, P.(4);Sehgal, T.(4);Midha, V.(4);Sood, A.(1);
(1)Dayanand Medical College and Hospital, Gastroenterology, Ludhiana, India;(2)Dayanand Medical College and Hospital, Pharmacology, Ludhiana, India;(3)Dayanand Medical College and Hospital, Pathology, Ludhiana, India;(4)Dayanand Medical College and Hospital, Medicine, Ludhiana, India;
P1105: Reswitching Anti-TNF’s as Third-Line Biologic Therapy After Second-Line Failures: Factors Influencing OutcomesECCO'25Year: 2025
Authors: Akpınar, A.(1)*;Gur, M.B.(2);Bakkaloglu, O.K.(3);Vatansever, H.(2);Eskazan, T.(1);Hatemi, A.I.(1);Erzin, Y.Z.(1);Celik, A.F.(1);
(1)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey;(2)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey;(3)Kosuyolu High Specialization Education and Research Hospital, Gastroenterology, Istanbul, Turkey;
P1108: Endoscopic Sleeve Gastroplasty for management of Obesity in patient suffer from Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Carlino, G.(1)*;Pontecorvi, V.(1);Bartocci, B.(2);Matteo, M.V.(1);Gualtieri, L.(3);De Siena, M.(1);Lopetuso, L.R.(4);Laterza, L.(4);Bove, V.(1);Pugliese, D.(4);Scaldaferri, F.(4);Spada, C.(1);Gasbarrini, A.(4);Boškoski, I.(1);
(1)Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore, Surgical Digestive Endoscopy, Rome, Italy;(2)Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore, Gastroenterology and Surgical Digestive Endoscopy, Rome, Italy;(3)Sapienza University of Rome, Department of Surgery, Rome, Italy;(4)Università Cattolica del Sacro Cuore- Fondazione Policlinico Gemelli IRCCS, Medicina Interna e Gastroenterologia- CEMAD Centro Malattie dell'Apparato Digerente- Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;
1.Johnson AM, Loftus EV. Impact of Obesity on the Management of Inflammatory Bowel Disease. Gastroenterology & Hepatology. 2020;16(7):350.
2.Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14(2):110-121. doi:10.1038/nrgastro.2016.181
3.Pugliese D, Schepis T, Bove V, Privitera G, Boskoski I, Armuzzi A. Morbidly Obese Patient With Ulcerative Colitis Treated With Endoscopic Gastroplasty: A Case Report. Inflammatory Bowel Diseases. 2021;27(4):e49-e50. doi:10.1093/ibd/izaa334
4.Johnson AM, Storm AC, Mahmoud T, et al. Endoscopic Bariatric Therapies for the Management of Obesity in Patients with Inflammatory Bowel Disease. OBES SURG. 2023;33(2):676-681. doi:10.1007/s11695-022-06376-3
